✦ LIBER ✦

41 Gefitinib for patients with advanced NSCLC treated on the expanded access programme: A institution experience

✍ Scribed by Cruz, M.; Katz, A.; Simon, S.; Tabacof, J.; Gansl, R.; Smaletz, O.

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

P-587 Experience from a large multi-cent

✍ van Puijenbroek, R.; Bosquée, L.; Tits, G.; Germonpre, P.; Strobbe, E.; Vansteen 📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 294 KB

Outcomes of patients with advanced non-s

✍ Jänne, Pasi A.; Gurubhagavatula, Sarada; Yeap, Beow Y.; Lucca, Joan; Ostler, Pat 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 134 KB

6608 POSTER An expanded access clinical

✍ Tewes, M.; Gauler, T.; Schuett, P.; Sailer, V.; Bildat, S.; Korfee, S.; Seeber, 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 58 KB

798 Impact of third line ZD 1839 therapy

✍ F. De Marinis; A. Mancuso; O. Martelli; M.R. Migliorino; R. Di Salvia 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 159 KB

A single-institution experience from the

✍ B. Kaufman; R. Weitzen; A. Goldfarb; N. Ephrat; I. Kuchuk; T. Golan; I. Wolf; R. 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 62 KB

Evaluation of the Sendai and 2012 Intern

✍ Goh, Brian K.P.; Thng, Choon-Hua; Tan, Damien M.Y.; Low, Albert S.C.; Wong, Jen- 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 222 KB